These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 22200414

  • 1. Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor.
    Sukumaran V, Veeraveedu PT, Gurusamy N, Lakshmanan AP, Yamaguchi K, Ma M, Suzuki K, Nagata M, Takagi R, Kodama M, Watanabe K.
    Mol Cell Endocrinol; 2012 Apr 04; 351(2):208-19. PubMed ID: 22200414
    [Abstract] [Full Text] [Related]

  • 2. Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 1-7 mas receptor.
    Sukumaran V, Veeraveedu PT, Lakshmanan AP, Gurusamy N, Yamaguchi K, Ma M, Suzuki K, Kodama M, Watanabe K.
    Free Radic Res; 2012 Jul 04; 46(7):850-60. PubMed ID: 22497476
    [Abstract] [Full Text] [Related]

  • 3. Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis.
    Sukumaran V, Veeraveedu PT, Gurusamy N, Yamaguchi K, Lakshmanan AP, Ma M, Suzuki K, Kodama M, Watanabe K.
    Int J Biol Sci; 2011 Jul 04; 7(8):1077-92. PubMed ID: 21927577
    [Abstract] [Full Text] [Related]

  • 4. Olmesartan, an AT1 antagonist, attenuates oxidative stress, endoplasmic reticulum stress and cardiac inflammatory mediators in rats with heart failure induced by experimental autoimmune myocarditis.
    Sukumaran V, Watanabe K, Veeraveedu PT, Gurusamy N, Ma M, Thandavarayan RA, Lakshmanan AP, Yamaguchi K, Suzuki K, Kodama M.
    Int J Biol Sci; 2011 Feb 11; 7(2):154-67. PubMed ID: 21383952
    [Abstract] [Full Text] [Related]

  • 5. Telmisartan acts through the modulation of ACE-2/ANG 1-7/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis.
    Sukumaran V, Veeraveedu PT, Gurusamy N, Lakshmanan AP, Yamaguchi K, Ma M, Suzuki K, Kodama M, Watanabe K.
    Life Sci; 2012 Feb 13; 90(7-8):289-300. PubMed ID: 22210452
    [Abstract] [Full Text] [Related]

  • 6. Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure.
    Yuan Z, Nimata M, Okabe TA, Shioji K, Hasegawa K, Kita T, Kishimoto C.
    Am J Physiol Heart Circ Physiol; 2005 Sep 13; 289(3):H1147-52. PubMed ID: 15879491
    [Abstract] [Full Text] [Related]

  • 7. Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice.
    Lakshmanan AP, Thandavarayan RA, Watanabe K, Sari FR, Meilei H, Giridharan VV, Sukumaran V, Soetikno V, Arumugam S, Suzuki K, Kodama M.
    Mol Cell Endocrinol; 2012 Jan 02; 348(1):104-11. PubMed ID: 21827824
    [Abstract] [Full Text] [Related]

  • 8. Candesartan cilexetil protects from cardiac myosin induced cardiotoxicity via reduction of endoplasmic reticulum stress and apoptosis in rats: involvement of ACE2-Ang (1-7)-mas axis.
    Arumugam S, Thandavarayan RA, Palaniyandi SS, Giridharan VV, Arozal W, Sari FR, Soetikno V, Harima M, Suzuki K, Kodama M, Watanabe K.
    Toxicology; 2012 Jan 27; 291(1-3):139-45. PubMed ID: 22120037
    [Abstract] [Full Text] [Related]

  • 9. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme.
    Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, Hyakkoku M, Taniguchi S, Shimamoto K.
    Hypertens Res; 2006 Nov 27; 29(11):865-74. PubMed ID: 17345786
    [Abstract] [Full Text] [Related]

  • 10. Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade.
    Igase M, Kohara K, Nagai T, Miki T, Ferrario CM.
    Hypertens Res; 2008 Mar 27; 31(3):553-9. PubMed ID: 18497476
    [Abstract] [Full Text] [Related]

  • 11. Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice.
    Patel VB, Bodiga S, Fan D, Das SK, Wang Z, Wang W, Basu R, Zhong J, Kassiri Z, Oudit GY.
    Hypertension; 2012 Jun 27; 59(6):1195-203. PubMed ID: 22508831
    [Abstract] [Full Text] [Related]

  • 12. Modulation of AT-1R/CHOP-JNK-Caspase12 pathway by olmesartan treatment attenuates ER stress-induced renal apoptosis in streptozotocin-induced diabetic mice.
    Lakshmanan AP, Thandavarayan RA, Palaniyandi SS, Sari FR, Meilei H, Giridharan VV, Soetikno V, Suzuki K, Kodama M, Watanabe K.
    Eur J Pharm Sci; 2011 Dec 18; 44(5):627-34. PubMed ID: 22033153
    [Abstract] [Full Text] [Related]

  • 13. Telmisartan ameliorates experimental autoimmune myocarditis associated with inhibition of inflammation and oxidative stress.
    Sukumaran V, Watanabe K, Veeraveedu PT, Ma M, Gurusamy N, Rajavel V, Suzuki K, Yamaguchi K, Kodama M, Aizawa Y.
    Eur J Pharmacol; 2011 Feb 10; 652(1-3):126-35. PubMed ID: 21115000
    [Abstract] [Full Text] [Related]

  • 14. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors.
    Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM.
    Hypertension; 2004 May 10; 43(5):970-6. PubMed ID: 15007027
    [Abstract] [Full Text] [Related]

  • 15. Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats.
    Varagic J, Ahmad S, VonCannon JL, Moniwa N, Brosnihan KB, Wysocki J, Batlle D, Ferrario CM.
    Am J Hypertens; 2013 May 10; 26(5):583-90. PubMed ID: 23459599
    [Abstract] [Full Text] [Related]

  • 16. Role of angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis in the hypotensive effect of azilsartan.
    Iwanami J, Mogi M, Tsukuda K, Wang XL, Nakaoka H, Ohshima K, Chisaka T, Bai HY, Kanno H, Min LJ, Horiuchi M.
    Hypertens Res; 2014 Jul 10; 37(7):616-20. PubMed ID: 24599018
    [Abstract] [Full Text] [Related]

  • 17. Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis.
    Nimata M, Kishimoto C, Yuan Z, Shioji K.
    Mol Cell Biochem; 2004 Apr 10; 259(1-2):217-22. PubMed ID: 15124927
    [Abstract] [Full Text] [Related]

  • 18. The counterregulating role of ACE2 and ACE2-mediated angiotensin 1-7 signaling against angiotensin II stimulation in vascular cells.
    Hayashi N, Yamamoto K, Ohishi M, Tatara Y, Takeya Y, Shiota A, Oguro R, Iwamoto Y, Takeda M, Rakugi H.
    Hypertens Res; 2010 Nov 10; 33(11):1182-5. PubMed ID: 20703229
    [Abstract] [Full Text] [Related]

  • 19. Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy.
    Sukumaran V, Watanabe K, Veeraveedu PT, Thandavarayan RA, Gurusamy N, Ma M, Yamaguchi K, Suzuki K, Kodama M, Aizawa Y.
    Exp Biol Med (Maywood); 2010 Nov 10; 235(11):1338-46. PubMed ID: 20876084
    [Abstract] [Full Text] [Related]

  • 20. Quercetin offers cardioprotection against progression of experimental autoimmune myocarditis by suppression of oxidative and endoplasmic reticulum stress via endothelin-1/MAPK signalling.
    Arumugam S, Thandavarayan RA, Arozal W, Sari FR, Giridharan VV, Soetikno V, Palaniyandi SS, Harima M, Suzuki K, Nagata M, Tagaki R, Kodama M, Watanabe K.
    Free Radic Res; 2012 Feb 10; 46(2):154-63. PubMed ID: 22145946
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.